Vericiguat: First Approval
Anthony Markham1, Sean Duggan2
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|March 26, 2021
Summary
Vericiguat, a novel soluble guanylate cyclase stimulator, is now approved for heart failure patients with reduced ejection fraction. This marks a significant advancement in managing chronic heart failure risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Drug Development
Background:
- Chronic heart failure (CHF) remains a leading cause of morbidity and mortality worldwide.
- Current treatments for CHF with reduced ejection fraction (HFrEF) have limitations in further reducing adverse events.
- Soluble guanylate cyclase (sGC) stimulation represents a novel therapeutic pathway for cardiovascular diseases.
Purpose of the Study:
- To summarize the key development milestones of vericiguat (VERQUVO™).
- To highlight the clinical evidence leading to the recent US approval of vericiguat.
- To provide an overview of vericiguat's mechanism of action in heart failure.
Main Methods:
- Review of preclinical and clinical development data for vericiguat.
- Analysis of the Phase III VICTORIA trial design and outcomes.
- Summary of regulatory submissions and approvals.
Main Results:
- Vericiguat is an oral stimulator of sGC, enhancing cyclic guanosine monophosphate (cGMP) production.
- It stimulates sGC independently of nitric oxide (NO) and potentiates NO-sGC signaling.
- The VICTORIA trial demonstrated a significant reduction in risk for heart failure events in patients with HFrEF.
Conclusions:
- Vericiguat offers a new therapeutic option for patients with symptomatic chronic heart failure and reduced ejection fraction.
- Its unique mechanism targeting the NO-sGC-cGMP pathway addresses unmet needs in CHF management.
- The approval of vericiguat signifies a milestone in the treatment paradigm for HFrEF.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
71
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
71
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
278
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
278
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.6K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
306
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
306
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
315
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
315
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
320
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
320